Pseudotime algorithms can be employed to extract latent temporal information from cross-11 sectional data sets allowing dynamic biological processes to be studied in situations where the 12 collection of genuine time series data is challenging or prohibitive. Computational techniques 13 have arisen from areas such as single-cell 'omics and in cancer modelling where pseudotime can 14 be used to learn about cellular differentiation or tumour progression. However, methods to date 15 typically assume homogenous genetic and environmental backgrounds, which becomes particu-16 larly limiting as datasets grow in size and complexity. As a solution to this we describe a novel 17 statistical framework that learns pseudotime trajectories in the presence of non-homogeneous 18 genetic, phenotypic, or environmental backgrounds. We demonstrate that this enables us to 19 identify interactions between such factors and the underlying genomic trajectory. By applying 20 this model to both single-cell gene expression data and population level cancer studies we show 21 that it uncovers known and novel interaction effects between genetic and enironmental factors 22 and the expression of genes in pathways. We provide an R implementation of our method 23 PhenoPath at https://github.com/kieranrcampbell/phenopath. 24 * c.yau@bham.ac.uk Dynamic or progressive biological behaviours are ideally studied within a longitudinal framework 26 that allows for monitoring of individuals over time leading to direct time course data. However, 27
Introduction
: Pseudotemporal analysis. A High-dimensional molecular data from a cross-sectional cohort is mapped on to a one-dimensional pseudotemporal progression scale allowing pseudotemporal behaviour of individual features to be analysed. B If the cohort contains sub-populations we may want each sub-population to be associated to distinct trajectories. C PhenoPath models observed expression as a combination of standard differential expression and pseudotime/pathway effects, including covariate-pathway interactions. D PCA representation of a simulated dataset coloured by pseudotime shows a clear splitting of trajectories between covariate status x = (−1, 1). E Simulation results showing the absolute value of the effect size reported by limma voom and the interaction coefficients β reported by PhenoPath under the four different simulation regimes and coloured by significance at 5% FDR.
For instance, a limitation of pre-existing pseudotime approaches is that they generally do not
We inferred a covariate-perturbed trajectory and uncovered a landscape of pseudotime-stimulant 140 interactions ( Fig. 2A) , unveiling genes whose regulation along pseudotime is modulated by the appli-141 cation of LPS or PAM. The trajectory inferred largely recapitulated the true time-series measurement 142 ( Fig. 2B , R 2 = 0.64), despite no explicit temporal information being provided to the algorithm, 143 though transcriptional heterogeneity at each time point is still evident. We also compared this to two 144 commonly-used pseudotime algorithms and found that the pseudotimes inferred using PhenoPath 145 had the best agreement with the capture times ( Supplementary Fig. 2) , possibly due to the ability 146 to integrate the confounding effect of differential stimulant exposure. 147 Using PhenoPath we discovered a large number of stimulant-modulated interactions masked by 148 standard differential-expression analysis (Fig. 2C ). A GO analysis revealed genes whose upregulation 149 along the common trajectory was increased by LPS exposure (as opposed to PAM) were highly 150 enriched for interferon-beta and immune response ( Fig. 2D ), which recapitulates previous results 151 [Shalek et al., 2014, Reid and Wernisch, 2016 ] that suggest a "core" module of antiviral genes 152 upregulated at later timepoints in LPS cells but in an entirely unsupervised, integrated manner. 153 We finally examined the individual genes most perturbed by LPS or PAM along the trajectory 154 ( Fig. 2E ), which identifies as yet uncharacterised expression patterns associated with LPS and 155 PAM. Most notably, the tumour necrosis factor Tnf had around twice the interaction effect size 156 of any other gene, and decreases under LPS stimulation but increases under PAM. Further genes The inferred pseudotimes (z) consistent with the physical capture times. C A comparison of p-values obtained through a nonparametric statistical test for differential expression between LPS and PAM stimulation shows no particular relation with the interaction parameters β inferred with PhenoPath. D A GO enrichment analysis of the genes upregulated along pseudotime whose upregulation was increased by LPS stimulation showed enrichment for immune system processes. E Expression of the four genes with the largest interaction effect sizes along over pseudotime, stratified by stimulant applied. Strikingly, Tnf is upregulated under PAM exposure yet downregulated under LPS stimulation.
Identifying microsatellite instability associated gene expression heterogeneity in colorectal cancer 163 We next applied our model to a non-single cell setting by examining RNA-seq gene expression data 164 from the TCGA colorectal adenocarcinoma (COAD) cohort [Network et al., 2012] . We used mi-165 crosatellite instability status (MSI) as a phenotypic covariate and wanted to identify pseudotemporal 166 expression patterns associated with MSI status. MSI is genetic hypermutability that is present in 167 around 15% of colorectal tumours and is associated with differential response to chemotherapeutics 168 and marginally improved prognosis [Boland and Goel, 2010] . 169 We applied PhenoPath to 4,801 highly variable genes across 284 samples to identify a pseu- interaction, while such interactions do not require differential expression.
183
The most striking interaction discovered for this dataset was the MLH1 gene whose interaction 184 effect size was far larger than any other gene. This association provided a positive control since 185 MLH1 is a DNA mismatch repair gene and germline mutations of which are causal for hereditary 186 non-polyposis colorectal cancer [Bonadona et al., 2011 , Gille et al., 2002 . By applying PhenoPath we 187 correctly identified that in patients, with low or absent levels of microsatellite instability, there is no 188 relationship between MLH1 expression and immune pathway interaction, with MLH1 expressed at 189 an approximately constant level ( Fig. 3E ). However, when MSI occurs in a tumour, MLH1 expression 190 is highly correlated with immune response, showing almost no expression when the immune pathway 191 is inactive and gradually being upregulated with immune pathway response [Michel et al., 2008] .
192
Tracking ER modulated angiogenesis driven progression in breast cancer 193 We next performed a pseudotemporal analysis of the TCGA breast cancer cohort using estrogen A PhenoPath applied to colorectal adenocarcinoma (COAD) RNA-seq expression data uncovers a landscape of interactions between the inferred immune trajectory and microsatellite instability status (MSI). B Expression of three T regulatory cell markers demonstrates that our pseudotime corresponds to activation of immune response pathways. C A comparison to the FDR-corrected q-values reported by Limma Voom demonstrates genes found interacting with MSI status and the immune pathway are found to be both DE and non-DE in standard analyses. D A GO enrichment analysis of upregulated genes implies the latent trajectory encodes immune pathway activation in each tumour. E The tumour suppressor genes MLH1 and TGFBR2 were identified by our method as being significantly perturbed along the immune trajectory by MSI status. MLH1 shows no interaction with immune pathway activation in the MSI-low regime yet is highly correlated with immune pathway activation in the MSI-high regime.
receptor positive [Early Breast Cancer Trialists' Collaborative Group (EBCTCG)], which is typically associated with improved prognosis and a longer time to recurrence [Parl et al., 1984] . We applied Figure 4 : Vascular growth-ER status interactions uncovered by PhenoPath in breast cancer. A PhenoPath applied to Breast Cancer (BRCA) RNA-seq expression data uncovers a landscape of interactions between the inferred angiogenesis trajectory and estrogen receptor (ER) status. B A comparison to the FDR-corrected q-values reported by Limma Voom identifies a significant number of DE genes display an interaction with ER status and the angiogenic pathway. C A GO enrichment analysis of upregulated genes implies the latent trajectory encodes angiogenesis pathway activation in each tumour. D Four example genes ESR1, FBP1, and FOXC1 were identified by PhenoPath as significantly perturbed along the angiogenesis trajectory by ER status. The vertical dashed line signifies the calculated crossover point, demonstrating the expression profiles of these genes converge towards the end of the trajectory. E A histogram of the crossover points of all genes whose trajectory-covariate interactions were significant. The vast majority of crossover points are at the end of the trajectory (around 0.5, where the "middle" pathway score is 0) implying a convergence of gene expression as the trajectory progresses.
the application of angiogenesis inhibitors in breast cancer treatment. et al., 2016 et al., , Datlinger et al., 2017 . We also demonstrated applications to The
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Cancer Genome Atlas using PhenoPath to model disease trajectories in colorectal and breast can-242 cer. The trajectories identified were consistent are consistent with pre-existing knowledge concerning 243 tumorigenesis in these disease. Importantly, PhenoPath was able to identify covariate-pathway in-244 teractions that might be driving specific trajectory differences recovering known associations as well 245 as novel genes. We showed that these behaviours cannot be readily determine with standard differ-246 ential expression analyses without taking into account the latent disease progression. In summary, We begin with an N × G data matrix Y where y ng denotes the n th entry in the g th column for n ∈ 1, . . . , N samples and g ∈ 1, . . . , G features. Such a matrix would correspond to the measurement of a dynamic molecular process that we might reasonably expect to show continuous evolution such as gene expression corresponding to a particular pathway. It is then trivial to learn a one-dimensional linear embedding that would be our "best guess" of such progression via a factor analysis model:
where z n is the latent measure of progression for sample n and λ g is the factor loading for feature 253 g which essentially describes the evolution of g along the trajectory.
254
However, it is conceivable that the evolution of feature g along the trajectory is not identical for all samples but is instead affected by a set of external covariates. Note that we expect such features to be "static" and should not correlate with the trajectory itself.
257
Introducing the N × P covariate matrix X with the entry in the n th row and p th column given by x np , we allow such measurements to perturb the factor loading matrix
where β pg quantifies the effect of covariate p on the evolution of feature g. Despite Y being columncentred we need to reintroduce gene and covariate specific intercepts to satisfy the model assumptions, giving a generative model of the form
Our goal is inference of z n that encodes progression along with β pg which is informative of novel interactions between continuous trajectories and external covariates. Consequently we place a sparse Bayesian prior on β pg of the form β pg ∼ N(0, χ −1 pg ) where the posterior of χ pg is informative of the model's belief that β pg is non-zero. The complete generative model is therefore given by
where τ α , τ λ , a, b, a β , b β , τ q are fixed hyperparameters and q n encodes prior information about z n 258 if available but typically q n = 0 ∀i in the uninformative case.
259
To understand this model it helps to consider the distribution of Y marginalised over the mapping {λ g , α pg , β pg } ∀ p, g with priors λ g ∼ N(0, τ −1 λ ) and α pg ∼ N(0, τ −1 α ). If y g denotes the column vectors of Y and similarly x p for X, [z] n = z n , 1 N is the column vector of ones and denotes the element-wise product, then
where
We therefore see that the addition of the covariates adds extra terms to the covariance matrix 260 corresponding to perturbations of the latent variables with the covariates. Consequently, the scale 261 on which x p is defined needs carefully calibrated. Furthermore, it is possible to extend the latent 262 variable matrix to have dimension larger than 1 giving a novel dimensionality reduction technique 263 for visualisation, though additional rotation issues arise.
264
Inference 265 We perform co-ordinate ascent mean field variational inference (see e.g. [Blei et al., 2016] ) with an approximating distribution of the form
Due to the model's conjugacy the optimal update for each parameter θ j given all other parameters θ −j can easily be computed via
where the expectation is taken with respect to the variational density over θ −j .
266
Identifying significant interactions 267
For each gene g and covariate p we have β pg that encodes the effect of p on the evolution of g along 268 the trajectory z. We would like to identify interesting or significant interactions for further analysis 269 and follow up.
270
The variational approximation for β pg is given by
We therefore define an interaction as significant if 0 falls outside the posterior nσ interval of m βpg . In other words, the interaction between p and g is significant if m βpg − ns βpg > 0 (10) or m βpg + ns βpg < 0 (11)
Note that variational inference typically underestimates posterior variances [Blei et al., 2016] so 271 such a designation of significant will be under-conservative. For all analyses we select n = 3, which 272 would loosely correspond to 0 being outside the 99.7% posterior interval of β pg .
273
Synthetic data study 274 We performed a small simulation study to identify effects uncovered by PhenoPath that are missed by standard differential expression analyses. Specifically, we sought to compare differentially expressed genes identified by limma voom [Law et al., 2014] , one of the leading RNA-seq differential expression methods, to the β interactions from PhenoPath. For N = 200 samples we assigned each to one of two categories given by the x values x = −1, 1, and assigned a pseudotime z through draws from a standard normal distribution. For each sample i = 1, . . . , N and gene g = 1, . . . , G we then generated a mean value through the PhenoPath mean function
The gene-specific parameters (α g , c g , β g ) were sampled in equal proportions from one of four In order to generate RNA-seq reads we need positive count values. In the spirit of general linear models, we then used g(x) = 2 x as a link function and generated a matrix of positive means
We subsequently simulated a count matrix c ig by sampling for each entry from a negative binomial distribution with meanμ ig and size parameterμ ig /3. While this could be used as input 284 to PhenoPath (suitable log transformed), we sought to make our simulation as realistic as possible 285 including quantification errors. We subsequently simulated FASTA files using the Bioconductor were used for input to limma voom.
291
In our simulation study, Limma Voom "only" detects 47% of the genes simulated as differentially 292 expressed. Such power to detect differential expression is dependent on effect sizes and measurement 293 noise, and so such a figure is in no way unreasonable given the parameters used. While a more 294 comprehensive simulation study could examine detection rates across entire distributions over effect 295 sizes and measurement noise, we simply sought to perform a simulation that demonstrated that
296
PhenoPath identifies a subset of differential expression and that standard differential expression 297 misses some interactions across a consistent effect size and noise regime. Shalek et al.
309
Preprocessed TPM values for all cells were retrieved from the Gene Expression Omnibus (GSE48968).
310
We retained cells treated by LPS and PAM at time points 1h, 2h, 4h, and 6h, resulting in 820 cells 311 (479 LPS and 341 PAM). We retained the 7533 genes whose variance in log 2 (TPM + 1) expression 312 was greater than 2. The first principal component of the data showed a strong dependency on the score of less than 0 and a PC3 score greater than -10, and removed any "normal" tumour types.
326
For input to PhenoPath we used the 4801 genes whose median absolute deviation in log(TPM + 1) 327 expression was greater than 1 
351
We fitted the crossover points z * for all significant genes in the BRCA dataset. We find that The condition for the crossover point is that the predicted expression for each phenotype is identical.
Therefore (in the context of BRCA cancer)
which leads to the condition
which is in turn solved by
Colas, Catherine Noguès, Sophie Lejeune-Dumoulin, Laurence Olivier-Faivre, Florence Polycarpe-Supplementary Figure 1 : Four gene expression simulation scenarios were used: (1) differential expression only where the overall expression level for groups -1 and 1 differed but there is no dependence on pseudotime or pathway score, (2) pseudotime regulation only where the overall marginal distribution of expression values is identical between groups but expression changes with latent pathway score, (3) pseduotime and covariate interactions where the trajectory for each group differs over pathway score and (4) a complex scenario where differential expression and covariate-pseudotime interactions all exist. 
